Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.
Orionis Biosciences has raised $55.0M in total funding. The most recent round was Series C. The last funding was announced in October 2022.
Orionis Biosciences's investors include Novartis, Cormorant Asset Management, V-Bio Ventures, Empire Angels, Excel Venture Management.
Orionis Biosciences is headquartered in Waltham, United States.
Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.
Orionis Biosciences is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orionis Biosciences — Funding & Investors." VCBacked, October 19, 2022, https://www.vcbacked.co/company/orionis-biosciences. Accessed August 14, 2026.
VCBacked. (2022). Orionis Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/orionis-biosciences
{{cite web |title=Orionis Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/orionis-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated